Key result
Statin therapy is associated with an increased risk of new-onset diabetes, particularly at higher doses and in susceptible groups, but the cardiovascular benefits significantly outweigh this risk.
Why the study?
Does statin therapy increase the risk of new-onset diabetes compared to placebo or lower doses in patients at risk for cardiovascular events?
Population
Patients receiving statins for primary or secondary cardiovascular prevention
Comparison
Statin therapy vs Placebo or moderate-dose statin therapy
Design
Review
Authors
Loading...
Supports statin use in high CV-risk patients with monitoring; leaves open dose optimization in susceptible subgroups.
Does statin therapy increase the risk of new-onset diabetes compared to placebo or lower doses in patients at risk for cardiovascular events?
Although statin therapy is associated with a small increased risk of new-onset diabetes, the cardiovascular benefits far outweigh this risk, supporting their continued use in at-risk patients.
Yoon et al. (2013) conducted a review in Cardiovascular disease and risk of new-onset diabetes. Statins vs. No statin or moderate-dose statin was evaluated. Statin therapy is associated with an increased risk of new-onset diabetes, particularly at higher doses and in susceptible groups, but the cardiovascular benefits significantly outweigh this risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: